A meta-analysis looked at 1,704 patients with gastric cancer to see how thymosin alpha1 works when combined with chemotherapy. The study compared this combination to chemotherapy alone. The researchers found that patients receiving the combination therapy showed higher overall response rates and better disease control. They also noted improvements in quality of life scores and several markers of immune system activity.
While the combination showed positive results in the short term, there are important reasons to be cautious. The evidence is considered low certainty because the included studies were all small and conducted in one country. Additionally, the studies did not provide data on long-term survival.
Patients should view these findings as an early indication of potential benefits rather than a proven long-term cure. Because the data is limited and the quality of the evidence is low, it is important to discuss these results with a doctor to understand how they might apply to a specific treatment plan.
